PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28460618-0	2019	Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.	Idarubicin	86-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26	
28460618-2	2019	OBJECTIVE: In the current study, HER2-specific affibody molecule, ZHER2:342 (an engineered protein with great affinity for HER2 receptors) was selected for conjugation to idarubicin (an anti-neoplastic antibiotic).	Idarubicin	171-181	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37	
28460618-2	2019	OBJECTIVE: In the current study, HER2-specific affibody molecule, ZHER2:342 (an engineered protein with great affinity for HER2 receptors) was selected for conjugation to idarubicin (an anti-neoplastic antibiotic).	Idarubicin	171-181	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71